The Hill  |  March 17, 2020

Read the Publication

Wash your hands. Practice social distancing. This often repeated and important public health messaging is critically important as the nation seeks to contain COVID-19.

Recently, CDC officials encouraged people to have a 2-week stock of their medications. Unfortunately, for people taking medications for opioid use disorder, this simply may not be possible — without critical federal intervention.

For people who use drugs or are in treatment for an opioid use disorder, the threat posed by COVID-19 may seem remote compared to the immediate risk of overdose, painful drug withdrawal, or the risk of HIV, viral hepatitis, or abscesses that can result from a disruption in harm reduction or effective treatment services.

Read the op-ed here.

Latest publications See All

Report

October 14, 2025

Charles Holmes Maggie Little, Ph.D.; Heidi Weimer, J.D., MPH, LL.M; Dylan Green, MPH; Alicia Patterson, Ph.D.; Jonathan Healey; Sydney Luken; Janet Tatenda Bhila; Aleny Couto, MD; Shona Dalal, PhD; Will Fleisher, PhD; Jen Gennai; Rayid Ghani; Peter Godfrey-Faussett; Melissa Goldstein, JD; Kathy Hageman, PhD, MPH; Nina Hasen, PhD; Micheal Ighodaro; Thoko Kalua, MBBS, MSc; Jennifer Miller, PhD; Yogan Pillay, PhD; Anton Pozniak, MD; Miriam Rabkin, MD, MPH; David Ribes, PhD; Lisa Singh, PhD